help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology Vol. 5, No. 10 1389-1395
doi:10.1210/mend-5-10-1389
Copyright © 1991 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bilezikjian, L. M.
Right arrow Articles by Vale, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bilezikjian, L. M.
Right arrow Articles by Vale, W.

Activin-A Inhibits Proopiomelanocortin Messenger RNA Accumulation and Adrenocorticotropin Secretion of AtT20 Cells

Louise M. Bilezikjian, Amy L. Blount, Carolyn A. Campen, Consuelo Gonzalez-Manchon and Wylie Vale*

The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute La Jolla, California 92037

Address requests for reprints to: Louise M. Bilezikjian, Ph.D., The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, 10010 North Torrey Pines Road, La Jolla, California 92037.

Abstract

The complexity of corticotropic cell regulation by multiple central and peripheral factors is well recognized. The present study provides evidence for the participation of an additional factor in the regulation of this cell type of the anterior pituitary. Using the clonal AtT20 cell line as a model for corticotropes, homodimeric activin-A was observed to suppress basal ACTH secretion and POMC mRNA accumulation by approximately 50%. These effects required prolonged treatment with activin-A and were concentration dependent; the half-maximum concentration was in the range of 30–50 pM. Consistently, AtT20 cells were found to express specific high affinity binding sites for [125I]activin-A. The simultaneous addition of inhibin-A along with increasing concentrations of activin-A did not alter the characteristics of the inhibition of ACTH secretion by activin-A alone. This is in contrast to observations with gonadotropes of the anterior pituitary as well as a number of other cell types in which inhibin-A can partially antagonize the biological actions of activin-A. The results may suggest the participation of a subclass of activin receptors that mediate effects on ACTH secretion and POMC mRNA accumulation. As previously shown, the incubation of AtT20 cells with a synthetic glucocorticoid, dexamethasone, attenuated basal ACTH secretion and POMC expression in a concentration-dependent manner. The inhibition of both of these parameters by activin-A, however, was independent of glucocorticoids, because the two agents were additive in their actions. In addition to effects on secretion and mRNA levels, treatment with activin-A also inhibited the rate of proliferation of AtT20 cells. In view of the recent evidence for the presence of activin-B, and possibly activin-A, within the anterior pituitary, the results of this study suggest that locally secreted activins may exert a tonic inhibitory influence on corticotropes.

FOOTNOTES

This work was supported in part by NIH Grants DK-26741 – 11 and HD-13527–12. Research was conducted in part by the Clayton Foundation for Research, California Division.

* Clayton Foundation Senior Investigator.

Received for publication June 5, 1991. Revision received July 18, 1991. Accepted for publication July 18, 1991.




This article has been cited by other articles:


Home page
Mol. Endocrinol.Home page
E. Wiater, K. A. Lewis, C. Donaldson, J. Vaughan, L. Bilezikjian, and W. Vale
Endogenous Betaglycan Is Essential for High-Potency Inhibin Antagonism in Gonadotropes
Mol. Endocrinol., July 1, 2009; 23(7): 1033 - 1042.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
E. Wiater, C. A. Harrison, K. A. Lewis, P. C. Gray, and W. W. Vale
Identification of Distinct Inhibin and Transforming Growth Factor beta-binding Sites on Betaglycan: FUNCTIONAL SEPARATION OF BETAGLYCAN CO-RECEPTOR ACTIONS
J. Biol. Chem., June 23, 2006; 281(25): 17011 - 17022.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
M. Nudi, J.-F. Ouimette, and J. Drouin
Bone Morphogenic Protein (Smad)-Mediated Repression of Proopiomelanocortin Transcription by Interference with Pitx/Tpit Activity
Mol. Endocrinol., May 1, 2005; 19(5): 1329 - 1342.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
S. C. Chapman and T. K. Woodruff
Betaglycan Localization in the Female Rat Pituitary: Implications for the Regulation of Follicle-Stimulating Hormone by Inhibin
Endocrinology, December 1, 2003; 144(12): 5640 - 5649.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
J.-F. Ethier, P. G. Farnworth, J. K. Findlay, and G. T. Ooi
Transforming Growth Factor-{beta} Modulates Inhibin A Bioactivity in the L{beta}T2 Gonadotrope Cell Line by Competing for Binding to Betaglycan
Mol. Endocrinol., December 1, 2002; 16(12): 2754 - 2763.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. C. Danila, X. Zhang, Y. Zhou, J. N. S. Haidar, and A. Klibanski
Overexpression of Wild-Type Activin Receptor Alk4-1 Restores Activin Antiproliferative Effects in Human Pituitary Tumor Cells
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4741 - 4746.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. M. O. Leal, K. Takabe, L. Wang, C. J. Donaldson, L. A. MacConell, L. M. Bilezikjian, I. M. Verma, and W. Vale
Effect of Adenovirus-Mediated Overexpression of Follistatin and Extracellular Domain of Activin Receptor Type II on Gonadotropin Secretion in Vitro and in Vivo
Endocrinology, March 1, 2002; 143(3): 964 - 969.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
D. J. Bernard, S. C. Chapman, and T. K. Woodruff
Minireview: Inhibin Binding Protein (InhBP/p120), Betaglycan, and the Continuing Search for the Inhibin Receptor
Mol. Endocrinol., February 1, 2002; 16(2): 207 - 212.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. A. Harrison, P. G. Farnworth, K. L. Chan, P. G. Stanton, G. T. Ooi, J. K. Findlay, and D. M. Robertson
Identification of Specific Inhibin A-Binding Proteins on Mouse Leydig (TM3) and Sertoli (TM4) Cell Lines
Endocrinology, April 1, 2001; 142(4): 1393 - 1402.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
L. M. Bilezikjian, A. Z. Corrigan, A. L. Blount, Y. Chen, and W. W. Vale
Regulation and Actions of Smad7 in the Modulation of Activin, Inhibin, and Transforming Growth Factor-{{beta}} Signaling in Anterior Pituitary Cells
Endocrinology, March 1, 2001; 142(3): 1065 - 1072.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. C. Danila, W. J. Inder, X. Zhang, J. M. Alexander, B. Swearingen, E. T. Hedley-Whyte, and A. Klibanski
Activin Effects on Neoplastic Proliferation of Human Pituitary Tumors
J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1009 - 1015.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
P. C. Gray, J. Greenwald, A. L. Blount, K. S. Kunitake, C. J. Donaldson, S. Choe, and W. Vale
Identification of a Binding Site on the Type II Activin Receptor for Activin and Inhibin
J. Biol. Chem., February 4, 2000; 275(5): 3206 - 3212.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
D. Engler, E. Redei, and I. Kola
The Corticotropin-Release Inhibitory Factor Hypothesis: A Review of the Evidence for the Existence of Inhibitory as Well as Stimulatory Hypophysiotropic Regulation of Adrenocorticotropin Secretion and Biosynthesis
Endocr. Rev., August 1, 1999; 20(4): 460 - 500.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
F. H. D’Abronzo, B. Swearingen, A. Klibanski, and J. M. Alexander
Mutational Analysis of Activin/Transforming Growth Factor-{beta} Type I and Type II Receptor Kinases in Human Pituitary Tumors
J. Clin. Endocrinol. Metab., May 1, 1999; 84(5): 1716 - 1721.
[Abstract] [Full Text]


Home page
J. Histochem. Cytochem.Home page
G. V. Childs and G. Unabia
Cytochemical Studies of the Effects of Activin on Gonadotropin-releasing Hormone (GnRH) Binding by Pituitary Gonadotropes and Growth Hormone Cells
J. Histochem. Cytochem., December 1, 1997; 45(12): 1603 - 1610.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
J. W. M. Martens, J. P. de Winter, M. A. Timmerman, A. McLuskey, R. H. N. van Schaik, A. P. N. Themmen, and F. H. de Jong
Inhibin Interferes with Activin Signaling at the Level of the Activin Receptor Complex in Chinese Hamster Ovary Cells
Endocrinology, July 1, 1997; 138(7): 2928 - 2936.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
D. Ray and S. Melmed
Pituitary Cytokine and Growth Factor Expression and Action
Endocr. Rev., April 1, 1997; 18(2): 206 - 228.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society